FATE THERAPEUTICS INC (FATE) Stock Analyst Ratings
USA - NASDAQ:FATE - US31189P1021 - Common Stock
0.964 USD
-0.03 (-2.85%)
0.9801 USD
+0.02 (+1.67%)
ChartMill assigns a Buy % Consensus number of 79% to FATE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.74. This target is 392.01% above the current price.
FATE was analyzed by 18 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about FATE.
In the previous month the buy percentage consensus was at a similar level.
FATE was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-31 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-27 | Needham | Reiterate | Hold -> Hold |
| 2025-10-27 | Wedbush | Upgrade | Neutral -> Outperform |
| 2025-08-13 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-12 | Needham | Reiterate | Hold -> Hold |
| 2025-05-14 | Needham | Reiterate | Hold -> Hold |
| 2025-05-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-14 | Baird | Maintains | Neutral -> Neutral |
| 2025-03-06 | Needham | Reiterate | Hold -> Hold |
| 2025-03-06 | Stifel | Maintains | Hold -> Hold |
| 2025-03-06 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-03-06 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-19 | Needham | Reiterate | Hold |
| 2024-11-13 | Needham | Reiterate | Hold |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-14 | Needham | Reiterate | Hold |
| 2024-06-17 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-05-16 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-05-10 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-05-10 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-05-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-05-06 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-04-23 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-04-11 | Needham | Reiterate | Hold |
| 2024-03-28 | B of A Securities | Maintains | Underperform -> Underperform |
| 2024-03-19 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-02-27 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-02-27 | Oppenheimer | Reiterate | Perform -> Perform |
| 2024-02-27 | Barclays | Maintains | Overweight -> Overweight |
FATE THERAPEUTICS INC / FATE FAQ
Can you provide the average price target for FATE THERAPEUTICS INC stock?
18 analysts have analysed FATE and the average price target is 4.74 USD. This implies a price increase of 392.01% is expected in the next year compared to the current price of 0.964.
What is the consensus rating for FATE stock?
The consensus rating for FATE THERAPEUTICS INC (FATE) is 78.8889 / 100 . This indicates that analysts generally have a positive outlook on the stock.